A Phase I Dose-Escalation Study of PHA-793887 Administered as a 1 Hour IV infusion for 5 Consecutive Days every 2 weeks or every 3 weeks in Patients with Advanced/Metastatic Solid Tumors

Trial Profile

A Phase I Dose-Escalation Study of PHA-793887 Administered as a 1 Hour IV infusion for 5 Consecutive Days every 2 weeks or every 3 weeks in Patients with Advanced/Metastatic Solid Tumors

Not stated
Phase of Trial: Phase I

Latest Information Update: 20 Nov 2007

At a glance

  • Drugs PHA 793887 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Nov 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top